Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Australian Ethical

            Deal Size: $22.4 million Upfront Cash: Undisclosed

            Deal Type: Financing November 19, 2020

            Details:

            The Company will use the proceeds to finance its LAG-3 related clinical program in immuno-oncology and autoimmune disease. The funds will also be used for the cell-line development of IMP761, R&D, manufacturing, the offering costs and working capital purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paxalisib

            Therapeutic Area: Oncology Product Name: GDC-0084

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            The new interim analysis of paxalisib phase II study in glioblastoma is highly consistent with prior data. Median progression-free survival (PFS) of 8.4 months reported on this analysis (versus 5.3 months for temozolomide, the existing standard of care).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Efti

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            The study is evaluating combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 03, 2020

            Details:

            More mature interim data from phase II TACTI-002 study of eftilagimod alpha has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paxalisib

            Therapeutic Area: Oncology Product Name: GDC-0084

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $25.2 million Upfront Cash: Undisclosed

            Deal Type: Public Offering October 23, 2020

            Details:

            Cash outflows are likely to increase as the Company proceeds with the GBM Agile trial, he pivotal study for registration of paxalisib in glioblastoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 18, 2020

            Details:

            TACTI-002 is being conducted in collaboration with Merck & Co and is evaluating the combination of Immutep’s lead candidate, eftilagimod alpha with MSD’s KEYTRUDA in up to 109 patients with second line Head and Neck Squamous Cell Carcinoma or NSCLC in first and second line.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 11, 2020

            Details:

            This U.S patent protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha and a chemotherapy agent.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMP701,Spartalizumab

            Therapeutic Area: Oncology Product Name: LAG525

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2020

            Details:

            This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eftilagimod Alpha,Pembrolizumab

            Therapeutic Area: Oncology Product Name: IMP321

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA and is evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paxalisib

            Therapeutic Area: Oncology Product Name: GDC-0084

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            Previous paxalisib data presented at ASCO was based on Stage 1 (n=9) of the ongoing phase II study in glioblastoma. This interim analysis at AACR includes all patients in the study (n=30), and therefore provides a more robust and substantial data set.

            PharmaCompass